The philosophy of Polaris Venture Partners can be summed up simply: diversity is good. That's why about a third of the investments Polaris has made from the $80 million fund raised at its founding in 1996 is in the life sciences; two-thirds are in information technology.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Chief Medical Officer Samit Hirawat will step down to pursue new career opportunities, the company said.
Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.
In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.
Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.
Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.
The Swiss giant has been talking to the US government about selling medicines directly to patients.
The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.
